Table 1.
Main characteristics of studies included in quantitative assessment
| Study | N | Group | Mean age in years ± SD | Illness duration/age at onset mean years ± SD | Daily dose (mg) | Treatment duration (weeks) | ||
|---|---|---|---|---|---|---|---|---|
| Raloxifene | Placebo | Raloxifene | Placebo | |||||
| Kulkarni et al. (2010)a | 21 | F (post) | 53.3 ± 8.0 | 50.9 ± 4.2 | 25.7 ± 10.1/ - | 11.6 ± 6.5 / - | 120 | 12 |
| Kulkarni et al. (2010)a | 14 | F (post) | 54.6 ± 4.6 | 50.9 ± 4.2 | 24.9 ± 11.5 / - | 11.6 ± 6.5 / - | 60 | 12 |
| Usall et al. (2011)/Huerta-Ramos et al. (2014)b | 33 | F (post) | 60.1 ± 6.41 | 62.7 ± 4.54 | 27.7 ± 6.97 / - | 25.2 ± 11.12 / - | 60 | 12 |
| Kianimehr et al. (2014) | 46 | F (post) | 62.0 ± 4.49 | 60.44 ± 5.28 | 17.2 ± 12.03 / 35.0 ± 11.69 | 13.6 ± 12.41 / 29.4 ± 8.57 | 120c | 8 |
| Khodaie-Ardakani et al. (2015) | 42 | M | 32.4 ± 7.8 | 31.4 ± 5.9 | 8.0 ± 3.83 / - | 7.4 ± 5.91 / - | 120c | 8 |
| Weickert et al. (2015) | 79 | M, F (pre + post) | 37.4 ± 7.3 | 34.0 ± 8.4 | 13.4 ± 7.5 / 24.1 ± 4.8 | 12.2 ± 7.2 / 22.1 ± 6.3 | 120 | 6 |
| Kulkarni et al. (2016) | 56 | F (per + post) | 52.9 ± 8.07 | 53.1 ± 7.43 | - / 27.9 ± 11.60 | - / 28.6 ± 12.34 | 120 | 12 |
| Usall et al. (2016) | 70 | F (post) | 62.0 ± 9.39 | 61.3 ± 10.41 | - / 26.3 ± 8.64 | - / 27.0 ± 11.37 | 60 | 24 |
| Weiser et al. (2017) | 200 | F (post) | 55.8 ± 4.7 | 56.6 ± 4.6 | - / 32.0 ± 9.5 | - / 31.1 ± 8.6 | 120 | 16 |
N sample size, SD standard deviation, F female, post postmenopausal, pre premenopausal, per perimenopausal, M male, mg milligram
aThe study by Kulkarni et al. (2010) administered two different dosages and, therefore, two effect sizes were extracted from each report. The reported N per effect size is number of patients in intervention group, plus a proportional amount of the number of patients in the placebo group
bThe papers by Usall et al. (2011) and Huerta-Ramos et al. (2014) are reported as one sample in this table, since they both report on the same sample and thus main characteristics are the same. N.B. Usall et al. (2016) reports on a different sample and is, therefore, presented separately
cAll participants received risperidon 6 mg in addition to raloxifene or placebo